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Clinical Implications of JUPITER (Justification for
the Use of statins in Prevention: an Intervention
Trial Evaluating Rosuvastatin) in a U.S. Population
Insights From the ARIC (Atherosclerosis Risk in Communities) Study
Eric Y. Yang, MD,*† Vijay Nambi, MD,*† Zhengzheng Tang, MS,§ Salim S. Virani, MD,*†
Eric Boerwinkle, PHD,‡ Ron C. Hoogeveen, PHD,*† Brad C. Astor, PHD, Thomas H. Mosley, PHD,¶
Josef Coresh, MD, PHD, Lloyd Chambless, PHD,§ Christie M. Ballantyne, MD*†
Houston, Texas; Chapel Hill, North Carolina; Baltimore, Maryland; and Jackson, Mississippi
Objectives The purpose of this study is to describe the proportion of “JUPITER-eligible” (Justification for the Use of statins in
Prevention: an Intervention Trial Evaluating Rosuvastatin) individuals and clinical outcomes of individuals based
on high-sensitivity C-reactive protein (hs-CRP) and low-density lipoprotein cholesterol (LDL-C) strata in the ARIC
(Atherosclerosis Risk in Communities) study.
Background Questions remain after the JUPITER study, including whether the observed cardiovascular disease (CVD) event
rates would persist with time and how these event rates would compare with other populations (lower hs-CRP
and/or higher LDL-C levels).
Methods After stratification into 4 groups based on LDL-C and hs-CRP levels, with cutoffs at 130 mg/dl and 2.0 mg/l,
respectively, incident CVD events were examined (mean follow-up, 6.9 years) and compared.
Results Of 8,907 age-eligible participants, 18.2% (n  1,621) were JUPITER-eligible (hs-CRP 2.0 mg/l, LDL-C 130 mg/dl)
and had an absolute CVD risk of 10.9% over a mean follow-up of 6.9 years (1.57% per year). If JUPITER hazard ra-
tios were applied to this group, the number needed to treat to prevent 1 CVD event would be estimated at 38
over 5 years and 26 over 6.9 years.
Conclusions ARIC participants with elevated hs-CRP and low LDL-C had a CVD event rate of 1.57% per year over 6.9
years, similar to the CVD event rate noted in the JUPITER study placebo group (1.36% per year over 1.9
years). The association of hs-CRP 2.0 mg/l with increased CVD risk and mortality regardless of LDL-C pro-
vides us a simple method of using age and hs-CRP level for identifying higher risk individuals. (Atheroscle-
rosis Risk in Communities study; NCT00005131) (J Am Coll Cardiol 2009;54:2388–95) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.006l
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osuvastatin) (1).
Questions remained at the conclusion of JUPITER,
ncluding: 1) would the absolute event rates and risk
eduction persist if the trial was continued for a longer time,
iven the short (1.9 years) follow-up; 2) what percentage of
he population may be eligible for therapy based on the
tudy; and 3) would similar findings have been observed if
ndividuals with hs-CRP 2.0 mg/l were included. Al-
hough randomized controlled trials may be required to
nswer some of these question (such as risk reduction),
opulation-based studies may be ideal to evaluate JUPI-
ER’s clinical implications and the natural history/event
ates in individuals with elevated hs-CRP and low LDL-C.
One analysis using the NHANES (National Health and
utrition Examination Survey) 1999 to 2004 data suggested
.07 million individuals (13.9%) of age-eligible individuals
ould meet JUPITER eligibility criteria (2), whereas an-
ther analysis suggested that 6.5 million individuals may
e eligible (3). However, these studies lacked longitudinal
ollow-up for outcomes and the ability to provide actual
VD risk in a population. Other primary prevention studies
ompared CVD event rates in individuals by hs-CRP and
DL-C groups, but these analyses were performed post-hoc
n randomized patients in clinical trials, making them prone
o selection bias; moreover, they used very different cutoff
evels for hs-CRP and LDL-C.
Therefore, we examined JUPITER’s clinical implications
n the ARIC (Atherosclerosis Risk in Communities) study,
population-based study of CVD disease incidence. We
ompared outcomes in the “JUPITER-eligible” group to
hose in the other LDL-C and hs-CRP level strata (i.e.,
s-CRP 2.0 mg/l and/or LDL-C 130 mg/dl).
ethods
tudy population. The design and objectives of the ARIC
tudy have been previously described (4). Briefly, the ARIC
tudy is a prospective, biracial, observational study of CVD in
5,792 individuals between ages 45 and 64 years at the
nitial visit (1987 and 1989). Our analysis used Visit 4 (1996
nd 1998) data, which had hs-CRP levels available in
1,343 of 11,656 individuals. We applied JUPITER exclu-
ion criteria (Fig. 1) except that peripheral vascular disease
PVD) and current hormone replacement therapy (HRT)
se in women were not excluded since adequate information
or these variables was not available during ARIC Visit 4.
fter exclusions, except for LDL-C and hs-CRP, there
ere 5,513 individuals, who were further stratified by
DL-C (130 mg/dl vs. 130 mg/dl) and hs-CRP (2.0
g/l vs. 2.0 mg/l) into 4 groups (Fig. 1).
aboratory methods. Plasma levels of hs-CRP were mea-
ured using an immunonephelometric assay (Dade Behring,
ewark, Delaware) (5) (reliability coefficient 0.99 based on21 blinded replicates). aefinition and ascertainment of
utcomes. Our primary outcome
f first major adverse cardiovascu-
ar event (MACE) was similar to
UPITER’s, which included non-
atal myocardial infarction (MI),
onfatal stroke, hospitalization for
nstable angina, coronary arterial re-
ascularization procedure (coronary
rterial bypass graft/percutaneous
oronary intervention), or con-
rmed cardiovascular death (fatal
oronary heart disease [CHD] or
atal stroke) except that fatal
troke (not previously defined
nd adjudicated in the ARIC
tudy) was not included, and fatal
HD was defined differently. Additionally, we evaluated a
econdary composite end point of nonfatal MI, fatal CHD,
onfatal stroke, and coronary revascularization (i.e., primary
nd point excluding unstable angina). Finally, as was done
n JUPITER, we evaluated deaths due to any cause or
alignancy (ICD-9 codes 140 to 208 or ICD-10 codes C00
o C97). The methods for ascertaining the various outcomes
n ARIC have been previously published (4,6–8).
tatistical analysis. The 4 groups (Fig. 1) were compared for
djusted means, proportions, or incidence rates using linear,
ogistic, or Poisson models. Model adjustments included age,
ace, and gender. Each group had 10-year CHD risk calculated
sing ARIC coronary risk score (ACRS) and Framingham risk
core (FRS), both calibrated to the ARIC initial examination
1986 to 1989) (9–11). Tests of contrasts of the beta coeffi-
ients from the linear or logistic regression models were used to
alculate p values. Hazard ratios (HRs) were calculated using
ox proportional hazard models to compare groups within
DL-C and hs-CRP strata. Kaplan-Meier event-free survival
rom any MACE was also examined.
We also tested whether significant cardiovascular risk due to
levated hs-CRP level persisted within each LDL-C stratum
fter further adjustments for smoking status, family history of
remature CHD, LDL-C levels, and Adult Treatment Panel
II–defined metabolic syndrome (12).
esults
f the total Visit 4 participants (n 11,656), 1,621 (683 men
nd 938 women) were age-eligible, met all screening criteria,
nd had LDL-C 130 mg/dl and hs-CRP 2.0 mg/l (i.e.,
UPITER-eligible). These 1,621 individuals (Group 2) con-
tituted 29.4% of the screened group (n 5,513) and 18.2% of
he age-eligible ARIC individuals (n  8,907) (Fig. 1).
In both LDL-C categories (i.e., LDL-C 130 mg/dl
nd 130 mg/dl), 50% of the individuals had hs-CRP
2.0 mg/l (Fig. 1). Individuals with hs-CRP 2.0 mg/l
ere more likely to be older, female, black, current smokers,
Abbreviations
and Acronyms
CHD  coronary heart
disease
CVD  cardiovascular
disease
hs-CRP  high-sensitivity
C-reactive protein
LDL-C  low-density
lipoprotein cholesterol
MACE  major adverse
cardiovascular event
MI  myocardial infarction
PVD  peripheral vascular
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Clinical Implications of JUPITER in the ARIC Study December 15/22, 2009:2388–95DL-C category, and had a higher prevalence of metabolic
yndrome, which was supported by higher waist circumfer-
nce, body mass index, systolic blood pressure, triglyceride
evel, and glucose level (Table 1).
The average predicted 10-year CHD risk of all groups
sing FRS or ACRS was “low” (i.e., 10-year CHD risk
10%) (Table 2). Individuals in the JUPITER-eligible
roup had the lowest average 10-year predicted CHD risk
sing either model (Table 2).
Over a mean follow-up of 6.9 years, the JUPITER-eligible
roup had a MACE rate of 15.73 events (primary outcome)
er 1,000 person-years (adjusted for age, race, and gender)
Group 1 
hs-CRP <2.0 mg/L 
LDL-C <130 mg/dL 
(n=1,614) 
Males 
(n=1,054) 
Females 
(n=560) 
Meeting age criteria  
(Men ≥ 50 yrs, Wome
(n=8,907) 
Assessed for eligibilit
Group 2 
hs-CRP ≥2.0 mg/L 
LDL-C <130 mg/dL 
(n=1,621) 
Males 
(n=683) 
Females 
(n=938) 
hs
LD
M
Fe
No Prior CVD or equi
(n=6,213) 
Eligible for Primary P
(n=5,513) 
LDL-C <130 mg/dL 
(n=3,235) 
JUPITER Eligible 
Figure 1 Individuals Meeting JUPITER Criteria After Exclusions
Inclusion and exclusion criteria are shown in sequential order of application to ind
high-sensitivity C-reactive protein (hs-CRP) and low-density lipoprotein cholesterol (
vascular disease.Table 3), which was elevated (HR: 1.65; 95% confidence anterval [CI]: 1.29 to 2.11) when compared with Group 1
LDL-C 130 mg/dl, hs-CRP 2.0 mg/l). Group 4
LDL-C 130 mg/dl, hs-CRP 2.0 mg/l) had a MACE
ate of 21.96 events per 1,000 person-years, which was
he highest of all 4 groups, significantly higher than
roup 3 (LDL-C 130 mg/dl, hs-CRP 2.0 mg/l; HR:
.80, 95% CI: 1.39 to 2.33), and nonsignificantly higher than
roup 2 (HR: 1.27, 95% CI: 0.96 to 1.67) (Table 4, Online
ig. 1). However, all-cause mortality and deaths due to cancer
ere highest in the JUPITER group (14.82 and 6.30 deaths
er 1,000 person-years, respectively). All event rates were
igher in the groups with the elevated hs-CRP (i.e., Groups 2
Excluded for age (n=2,313) 
(Men < 50 yrs, Women < 60 yrs) 
Excluded for race other white or black  
(n=25) 
Missing pertinent data (n=411) 
Missing LDL-C data 
(n=224) 
Missing hs-CRP data 
(n=187)  yrs) 
1,656)
roup 3 
 <2.0 mg/L 
≥130 mg/dL 
,132) 
49) 
 
83) 
Group 4 
hs-CRP ≥2.0 mg/L 
LDL-C ≥130 mg/dL 
(n=1,146) 
Males 
(n=533) 
Females 
(n=613) 
Prevalent CVD or Diabetes (n=2,521 
and 173 missing data) 
Prior history of ischemic stroke 
(n=223 and 15 missing data) 
Prior history of CHD 
(n=818 and 157 missing data) 
Diabetes 
(n=1,480 and 1 missing data)
   
tion  
LDL-C ≥ 130 mg/dL 
(n=2,278) 
JUPITER Exclusions for Primary 
Prevention (n=687 and 13 missing 
data) 
Creatinine > 2.0 mg/dL 
(n=9 and 0 missing data) 
On lipid-lowering therapy 
(n=678 and 13 missing data) 
Triglycerides ≥ 500 mg/dL 
(n=0 and 0 missing data) 
e ARIC Population (1996 to 1998)
s at the 1996 to 1998 visit in the ARIC study. The group (Group 2) meeting the
criteria of the JUPITER study has been labeled “JUPITER Eligible.” CVD  cardio-n ≥ 60
y (n=1
G
-CRP
L-C 
(n=1
ales 
(n=6
males
(n=4
valent
reven
in th
ividual
LDL-C)nd 4) for both LDL-C strata. Lower probability of event-free
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lso shown by Kaplan-Meier models (Fig. 2). Men with
levated hs-CRP had greater event rates for all outcomes in all
roups (Tables 3 and 4). The number of clinical events in each
roup and by gender is shown in Online Tables 1 and 2.
After additional adjustments as detailed in the Methods
ection, the hazard ratios comparing hs-CRP 2.0 mg/l
ith 2.0 mg/l (i.e., Group 2 vs. 1 and Group 4 vs. 3) for
ACE, mortality, and cancer deaths remained significant
linical Characteristics by LDL-C/hs-CRP Categories, Adjusted forTable 1 Clinical Characteristics by LDL-C/hs-CRP Categories, A
Variable
Group 1
(LDL-C <130 mg/dl,
hs-CRP <2.0 mg/l)
(n  1,614)
Group 2
(LDL-C <130 mg/d
hs-CRP >2.0 mg/
(n  1,621)
Age (yrs) 64.1 (0.12) 64.3 (0.12)
Males (%) 64 (0.012) 43 (0.012)
Whites (%) 84 (0.009) 78 (0.010)
Waist circumference (cm) 96.4 (0.32) 103.1 (0.32)
Body mass index (kg/m2) 26.5 (0.12) 29.1 (0.12)
Hypertensive (%) 35 (0.012) 47 (0.012)
Systolic blood pressure (mm Hg) 125.4 (0.45) 128.2 (0.45)
Diastolic blood pressure (mm Hg) 71.0 (0.25) 71.0 (0.24)
Self-reported antihypertensive use in
last 2 weeks before visit (%)
23 (0.011) 34 (0.012)
Metabolic syndrome (%) 19 (0.010) 33 (0.012)
Aspirin use (%) 47 (0.013) 52 (0.013)
Current smoker (%) 13 (0.008) 17 (0.010)
Former smoker (%) 44 (0.012) 45 (0.012)
Nonsmoker (%) 44 (0.012) 38 (0.012)
Family history of premature CHD (%) 8 (0.007) 9 (0.008)
Total cholesterol (mg/dl) 180.7 (0.62) 179.3 (0.62)
Triglycerides (mg/dl) 114.6 (1.54) 133.4 (1.54)
HDL-C (mg/dl) 54.6 (0.38) 50.8 (0.38)
Calculated LDL-C (mg/dl) 103.2 (0.52) 101.8 (0.52)
Non–HDL-C (mg/dl) 126.1 (0.63) 128.5 (0.62)
Glucose (mg/dl) 97.5 (0.22) 99.4 (0.22)
hs-CRP (mg/l)* 0.9 4.7
ll values are percent or mean (standard error), unless otherwise stated. *Unadjusted medians. For
or race and sex; race, for age and sex; and sex, for age and race).
CHD  coronary heart disease; HDL-C  high-density lipoprotein cholesterol; hs-CRP  high-se
ategorization of Individuals* by 10-Year CHD Risk Calculated by FTable 2 Categorization of Individuals* by 10-Year CHD Risk Ca
Variable
Group 1
(LDL-C <130 mg/dl,
hs-CRP <2.0 mg/l)
Group 2
(LDL-C <130 mg/dl,
hs-CRP >2.0 mg/l)
Mean Framingham 10-year risk 5.0% 4.7%
Framingham risk 5% 980 (60.7%) 1,114 (68.7%)
Framingham risk 5%–10% 467 (28.9%) 306 (18.9%)
Framingham risk 10%–20% 147 (9.1%) 171 (10.5%)
Framingham risk 20% 13 (0.8%) 19 (1.2%)
Mean ARIC 10-year risk 5.9% 5.6%
ARIC risk 5% 801 (49.6%) 927 (57.2%)
ARIC risk 5%–10% 514 (31.8%) 377 (23.3%)
ARIC risk 10%–20% 264 (16.4%) 266 (16.4%)
ARIC risk 20% 19 (1.2%) 33 (2.0%)
xcept for mean 10-year CHD risks, values for risk categories are number (proportion). The omnibu
ategories was significant (p  0.0001) for risk determined by the Framingham and the ARIC risk scores
ARIC  Atherosclerosis Risk in Communities; other abbreviations as in Table 1.Online Table 3); however, the hazard ratios comparing
DL-C 130 mg/dl with 130 mg/dl (i.e., Group 3 vs. 1
nd Group 4 vs. 2) for the same outcomes, except mortality,
ecame nonsignificant (Online Table 3).
iscussion
t the end of the JUPITER study, questions remained
13) as detailed earlier. Our analysis examined some of
Sex, and Raceted for Age, Sex, and Race
p Value
(Comparing
oups 1 and 2)
Group 3
(LDL-C >130 mg/dl,
hs-CRP <2.0 mg/l)
(n  1,132)
Group 4
(LDL-C >130 mg/dl,
hs-CRP >2.0 mg/l)
(n  1,146)
p Value
(Comparing
Groups 3 and 4)
0.17 63.8 (0.15) 64.4 (0.15) 0.002
0.0001 56 (0.014) 48 (0.014) 0.0001
0.0001 84 (0.011) 78 (0.012) 0.0001
0.0001 97.4 (0.38) 104.6 (0.38) 0.0001
0.0001 26.9 (0.15) 29.3 (0.14) 0.0001
0.0001 39 (0.014) 43 (0.014) 0.03
0.0001 127.1 (0.54) 128.8 (0.53) 0.03
0.995 71.6 (0.29) 71.6 (0.29) 0.91
0.0001 26 (0.013) 29 (0.013) 0.07
0.0001 25 (0.013) 40 (0.014) 0.0001
0.02 46 (0.015) 52 (0.015) 0.005
0.0002 10 (0.009) 21 (0.012) 0.0001
0.35 41 (0.014) 43 (0.015) 0.27
0.0002 49 (0.015) 36 (0.014) 0.0001
0.30 10 (0.009) 10 (0.010) 0.51
0.11 231.2 (0.74) 230.8 (0.73) 0.75
0.0001 129.6 (1.83) 145.6 (1.82) 0.0001
0.0001 49.9 (0.45) 45.8 (0.44) 0.0001
0.06 155.3 (0.62) 156.0 (0.61) 0.46
0.008 181.3 (0.74) 185.1 (0.74) 0.0003
0.0001 98.7 (0.27) 100.7 (0.26) 0.0001
1.0 4.4
ce, and sex, each of these variables were adjusted for the other 2 variables (i.e., age was adjusted
C-reactive protein; LDL-C  low-density lipoprotein cholesterol.
ngham Risk Score and ARIC Risk Scoreted by Framingham Risk Score and ARIC Risk Score
p Value
omparing
ps 1 and 2)
Group 3
(LDL-C >130 mg/dl,
hs-CRP <2.0 mg/l)
Group 4
(LDL-C >130 mg/dl,
hs-CRP >2.0 mg/l)
p Value
(Comparing
Groups 3 and 4)
0.0001 6.3% 7.1% 0.0001
0.0001 559 (49.4%) 586 (51.1%) 0.0001
0.0001 371 (32.8%) 289 (25.2%) 0.0001
0.0001 184 (16.3%) 220 (19.2%) 0.0001
0.0001 16 (1.4%) 45 (3.9%) 0.0001
0.0001 8.2% 9.0% 0.0001
0.0001 454 (40.1%) 459 (40.1%) 0.0001
0.0001 301 (26.6%) 270 (23.6%) 0.0001
0.0001 314 (27.7%) 298 (26.0%) 0.0001
0.0001 59 (5.2%) 109 (9.5%) 0.0001
f any difference between the 4 LDL-C by hs-CRP groups in the distribution among the 4 risk-levelAge,djus
l,
l)
Gr
age, raramilcula
(C
Grou










s test o
. *48 excluded due to missing variables.
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Clinical Implications of JUPITER in the ARIC Study December 15/22, 2009:2388–95hese questions in the ARIC study and compared the
haracteristics, predicted 10-year CHD risk, and actual
ardiovascular event rates over a long-term follow-up of
hose who were and were not JUPITER-eligible.
ardiovascular risk in JUPITER-eligible ARIC partici-
ants over longer follow-up. The MACE rates in the
UPITER-eligible group in our study over a mean
ollow-up of 6.9 years was similar to the JUPITER placebo
rm (Tables 5 and 6) (1), suggesting that the event rates
bserved in JUPITER are likely to persist over longer
bservation periods. When the event reduction observed
ith rosuvastatin in JUPITER was applied to our
Event Rates per 1,000 Person-Years Adjusted foTable 3 Event Rates per 1,000 Person-Year
Variable
Group 1
(LDL-C <130 mg/dl,
hs-CRP <2.0 mg/l)
(LDL-
hs-CR
Overall
All major CV events 9.56
All MI, CVA, CABG/PTCA 8.80
All-cause death 9.51
Death due to cancer 3.74
Men
All major CV events 13.47
All MI, CVA, CABG/PTCA 12.44
All-cause death 11.25
Death due to cancer 4.57
Women
All major CV events 5.70
All MI, CVA, CABG/PTCA 5.27
All-cause death 7.28
Death due to cancer 3.10
CABG/PTCA coronary arterial bypass graft/percutaneous translumin
accident; MI  myocardial infarction; other abbreviations as in Table
Rs (95% CI) Adjusted for Age, Race, and Sex Comparing hs-CRPithin Each LDL-C Strata and Comparing LDL-C Groups (>130 mg/Table 4 HRs (95% CI) justed for Age, Race, and Sex Co paWithin Each LDL-C Strata and Comparing LDL-C Groups
Comparison of hs-CRP Groups Within Each LDL
HR (95% CI)
(Comparing
Group 2 vs. 1)
p Values
(Comparing
Group 2 vs. 1)
HR (95% CI)
(Comparing
Group 4 vs. 3)
Overall
All major CV events 1.65 (1.29–2.11) 0.0001 1.80 (1.39–2.33)
All MI, CVA, CABG/PTCA 1.60 (1.25–2.07) 0.0002 1.94 (1.48–2.53)
All-cause death 1.66 (1.30–2.11) 0.0001 1.59 (1.16–2.19)
Death due to cancer 1.71 (1.17–2.49) 0.006 1.66 (1.03–2.68)
Men
All major CV events 1.56 (1.15–2.10) 0.004 2.06 (1.50–2.83)
All MI, CVA, CABG/PTCA 1.52 (1.12–2.07) 0.008 2.18 (1.58–3.01)
All-cause death 1.95 (1.45, 2.62) 0.0001 1.42 (0.96–2.09)
Death due to cancer 1.85 (1.16–2.95) 0.01 2.03 (1.10–3.74)
Women
All major CV events 1.79 (1.13–2.83) 0.01 1.40 (0.90–2.20)
All MI, CVA, CABG/PTCA 1.70 (1.06–2.72) 0.03 1.57 (0.97–2.52)
All-cause death 1.18 (0.78–1.80) 0.43 1.95 (1.12–3.37)
Death due to cancer 1.42 (0.75–2.67) 0.28 1.13 (0.52–2.45)I  confidence interval; HR  hazard ratio; other abbreviations as in Tables 1 and 3.UPITER-eligible group, we determined the number
eeded to treat to prevent 1 first MACE was 38 individ-
als over 5 years and 26 over 6.9 years using the Altman-
ndersen method.
omparison of 10-year cardiovascular risk by LDL-C
nd hs-CRP groupings and its clinical implications.
lthough individuals in the JUPITER-eligible group numer-
cally had the lowest average 10-year–predicted CHD risk,
hey had a significantly higher MACE rate compared with
roup 1, and a numerically higher MACE rate compared with
ndividuals of Group 3. Group 4 individuals numerically had
he highest average 10-year–predicted CHD risk and the
e, Race, and Sexusted for Age, Race, and Sex
2
0 mg/dl,
.0 mg/l)
Group 3
(LDL-C >130 mg/dl,
hs-CRP <2.0 mg/l)
Group 4
(LDL-C >130 mg/dl,
hs-CRP >2.0 mg/l)
3 12.17 21.96
2 10.56 20.22
2 7.73 12.29
0 3.29 5.44
5 16.20 34.26
8 14.55 31.17
1 11.06 15.63
1 3.86 7.82
3 8.20 12.60
4 6.63 11.62
2 4.45 8.62
6 2.83 3.17
ary angioplasty; CV cardiovascular disease; CVA cerebrovascular
s (>2.0 to <2.0 mg/l)<130) Within Each hs-CRP Strata-CRP Groups (>2.0 to <2.0 mg/l)
30 mg/dl to <130) Within Each hs-CRP Strata
ata Comparison of LDL-C Groups Within Each hs-CRP Strata
alues
mparing
4 vs. 3)
HR (95% CI)
(Comparing
Group 3 vs. 1)
p Values
(Comparing
Group 3 vs. 1)
HR (95% CI)
(Comparing
Group 4 vs. 2)
p Values
(Comparing
Group 4 vs. 2)
.0001 1.38 (1.11–1.73) 0.005 1.27 (0.96–1.67) 0.09
.0001 1.46 (1.16–1.83) 0.001 1.21 (0.91–1.60) 0.20
.004 0.82 (0.64–1.05) 0.12 0.85 (0.63–1.17) 0.32
.04 0.86 (0.59–1.25) 0.43 0.88 (0.55–1.42) 0.61
.0001 1.60 (1.20–2.14) 0.001 1.21 (0.87–1.68) 0.25
.0001 1.68 (1.26–2.26) 0.0005 1.18 (0.84–1.64) 0.34
.08 0.71 (0.52–0.98) 0.04 0.98 (0.68–1.42) 0.92
.02 0.93 (0.58–1.51) 0.78 0.85 (0.47–1.55) 0.59
.14 1.10 (0.77–1.57) 0.61 1.40 (0.83–2.39) 0.21
.06 1.16 (0.80–1.67) 0.44 1.26 (0.72–2.19) 0.42
.018 1.01 (0.68–1.48) 0.97 0.61 (0.35–1.09) 0.09
.77 0.73 (0.39–1.35) 0.31 0.92 (0.42–2.02) 0.83r Ags Adj
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rom primary prevention trials which showed that the highest
ncidence of CVD occurred in “high” LDL-C and “high”
s-CRP groups (14,15).
Comparison of ARIC JUPITER-Eligible Group, JUPPlacebo Arm, and JUPITER Treated Arm: BaselinTable 5 Comparison of ARIC JUPITER-EligibPlacebo Arm, and JUPITER Treated
Variable
ARIC Group 2*
(n  1,621)
(Over 6.9 yrs)
Age (yrs) 64.6
Male (%) 42
White (%) 78
Body mass index (kg/m2) 29.1
Systolic blood pressure (mm Hg) 128.2
Diastolic blood pressure (mm Hg) 71.0
Current smoker (%) 17
Family history of premature CHD (%) 9
Metabolic syndrome (%) 33
Aspirin use (%) 52
Total cholesterol (mg/dl) 179.3
Triglycerides (mg/dl) 133.4
HDL-C (mg/dl) 50.8
LDL-C (mg/dl) 101.8
Fasting glucose (mg/dl) 99.4
Median hs-CRP (mg/l) 4.7
*All statistics from the ARIC study are means or proportions unless o
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Group 1
(LDL-C < 130 mg/dL,
hs-CRP < 2.0 mg/L)
Group 2
(LDL-C < 130 mg/dL,
hs-CRP ≥ 2.0 mg/L)
Group 3
(LDL-C ≥ 130 mg/dL,
hs-CRP < 2.0 mg/L)
Group 4
(LDL-C ≥ 130 mg/dL,
hs-CRP ≥ 2.0 mg/L)
Figure 2 Kaplan-Meier Cardiovascular Event-Free Survival Curve
Cardiovascular event-free survival curves for the 4 groups are shown between 199
6.9 years). At the end of available follow-up, the groups in descending order of proJUPITER  Justification for the Use of statins in Prevention: an Interventio
abbreviations as in Tables 1 to 3.On the basis of the known benefit of statins in those with
DL-C 130 mg/dl, it would be ethically difficult to
onduct a placebo-controlled study in patients with LDL-C
130 mg/dl and hs-CRP 2.0 mg/l. Clinicians, therefore,
aracteristicsup, JUPITER
Baseline Characteristics
JUPITER Placebo Arm†
(n  8,901)
(Over 1.9 yrs)
JUPITER Treated Arm†
(n  8,901)
(Over 1.9 yrs)
66.0 66.0
62.1 61.5
71.1 71.4
28.4 28.3
134 134
80 80
16.0 15.7
11.8 11.2
41.8 41.0
16.6 16.6
185 186
118 118
49 49
108 108
94 94
4.3 4.2
e stated; †all statistics from JUPITER are medians or proportions.
5 6 7 8 9
up (yrs)
the 4 Groups Analyzed
998 and December 31, 2005 (mean follow-up
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atients with hs-CRP2.0 mg/l for statin treatment for the
rimary prevention of CVD.
revalence and characteristics of the ARIC population
eeting JUPITER criteria (Group 2). The JUPITER-
ligible individuals in our study were similar to the treated
nd placebo arms of JUPITER at baseline; however, our
tudy had more women and greater aspirin use (Table 5) (1).
ur study showed that 18.2% of age-eligible individuals
et LDL-C and hs-CRP criteria, which was similar to the
9.8% reported in JUPITER. However, a NHANES anal-
sis showed only 13.9% of the age-eligible American
opulation to be eligible (2). Therefore, the actual preva-
ence of JUPITER-eligible Americans may range between
14% and 20%. However, 50% of either LDL-C strata
i.e., LDL-C 130 and 130 mg/dl) had hs-CRP 2.0
g/l in our study. Therefore, if all individuals with hs-CRP
2.0 mg/l were considered eligible for statins (although not
ested in JUPITER), the number would be significantly
igher.
ther observations. Groups with elevated hs-CRP
Groups 2 and 4) had significantly higher all-cause and
ancer mortality than their counterparts with low hs-CRP
Groups 1 and 3). Groups with high LDL-C (Groups 3 and
) had nonsignificantly higher all-cause and cancer mortal-
ty than their counterparts with low LDL-C (Groups 1 and
) (Table 4). Malignancy and inflammatory disorders were
ot excluded since they were not previously defined in the
RIC study. Regardless, it appears that those with elevated
s-CRP may have increased mortality, which may merits
urther investigation.
Higher proportions of women were observed in groups with
s-CRP 2.0 mg/l (Groups 2 and 4). Overall, women with
s-CRP 2.0 mg/l had higher event rates compared with
ounterparts with hs-CRP 2.0 mg/l. Importantly, despite
omen being generally considered at lower CVD risk than
en, they were the majority in groups with hs-CRP 2.0
g/l, which had the highest event rates.
Last, CVD risk and mortality remained significantly in-
Comparison of ARIC JUPITER-Eligible Group,JUPITER Placebo Arm, and JUPITER Treated ArmTable 6 Compa ison of ARIC JUPITER-EligibJUPITER Placebo Arm, and JUPITER
Outcome
ARIC Group 2*
(n  1,621)
(Over 6.9 yrs)
JUPITER Place
(n  8,9
(Over 1.9
All major CV events 15.7 13.6
All-cause death 14.8 12.5
Revascularization
(CABG/PTCA)
6.7 7.1
Unstable angina 4.7 1.4
Hospitalized myocardial
infarction
4.8 3.3
Hospitalized strokes 4.2 3.1
Event rates per 1,000 person-years. *All statistics from the ARIC study a
are medians or proportions.
Abbreviations as in Tables 1, 2, 3, and 5.reased in those with elevated hs-CRP (Groups 2 and 4) even after further adjustments for other risk factors. This finding
uggests an association of elevated hs-CRP with increased
ardiovascular risk independent of “traditional” risk factors.
ikewise, the increased cancer death risk associated with
levated hs-CRP remained significant within each LDL-C
tratum after these adjustments. Therefore, based on JUPI-
ER and our analysis, the mere utilization of age (men50
ears, women 60 years) and hs-CRP 2.0 mg/l identified
population at higher CVD and mortality risk, which may
e decreased with statin therapy. This simple way of
dentifying higher-risk individuals using these 2 variables
ill make it easier for clinicians without having to use risk
quations.
tudy limitations. The ARIC population consists pre-
ominantly of whites and blacks, limiting the generalizabil-
ty to other ethnicities. HRT use in women (an exclusion
riteria in JUPITER) and PVD presence were not excluded
see Methods section). JUPITER excluded only those with
“history” of symptomatic PVD and did not measure
nkle-brachial indices on all participants. Other JUPITER
xclusion criteria (e.g., immunosuppressant use, rheumato-
ogic diseases, malignancy, inflammatory bowel disease,
levated creatinine kinase 3 times the upper limit of
ormal, or thyroid disorders) were not available for the
RIC participants.
onclusions
ur study showed that 18.2% of the age-eligible ARIC
opulation would have been eligible for JUPITER, and they
ad an absolute CVD risk of 10.9% over 6.9 years,
uggesting the CVD risk observed in the JUPITER study
ay persist over an extended period of time. Our study in
oncert with JUPITER supports a simple method of using
ge and hs-CRP for identification of higher-risk individuals.
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